Fingerprint
Dive into the research topics of 'Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
for Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups*
- University of Oklahoma
- Groupe Hospitalier Diaconesses–Croix
- University of California at Los Angeles
- Parc Taulí Research and Innovation Institute
- Royal Marsden NHS Foundation Trust
- Catholic University of Sacred Heart
- Yonsei University
- Samsung Medical Center, Sungkyunkwan university
- The University of Chicago
- IRCCS Istituto Europeo di Oncologia - Milano
- University of Milan - Bicocca
- University of Medical Sciences Poznan
- Academic Medical Centre
- University of Massachusetts Boston
- Meir Hospital Sapir Medical Center
- Ohio State University
- Charles University
- University of Pennsylvania
- CNRS
- Arizona Oncology Associates
- Hospital Universitario Virgen del Rocio
- University of Pittsburgh
- University College London
- University of Virginia
- IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
- Hospital Universitario de Jaén
- ImmunoGen Inc
- Institut Curie
- KU Leuven
Research output: Contribution to journal › Article › peer-review
71
Scopus
citations